Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average (2016 - 2025)

Historic Equity Average for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to $1.2 billion.

  • Agios Pharmaceuticals' Equity Average fell 2178.87% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year decrease of 2178.87%. This contributed to the annual value of $1.4 billion for FY2025, which is 1624.57% up from last year.
  • Agios Pharmaceuticals' Equity Average amounted to $1.2 billion in Q4 2025, which was down 2178.87% from $1.3 billion recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year Equity Average high stood at $2.0 billion for Q2 2021, and its period low was $702.2 million during Q2 2024.
  • Moreover, its 5-year median value for Equity Average was $1.2 billion (2022), whereas its average is $1.2 billion.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 23946.34% in 2021, then plummeted by 4197.95% in 2022.
  • Agios Pharmaceuticals' Equity Average (Quarter) stood at $1.3 billion in 2021, then fell by 19.94% to $1.1 billion in 2022, then fell by 21.07% to $848.9 million in 2023, then surged by 86.57% to $1.6 billion in 2024, then dropped by 21.79% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.3 billion for Q3 2025, and $1.4 billion during Q2 2025.